nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—ABCG2—Topotecan—cervical cancer	0.215	0.634	CbGbCtD
Sorafenib—ABCB1—Topotecan—cervical cancer	0.0777	0.229	CbGbCtD
Sorafenib—CYP3A4—Topotecan—cervical cancer	0.0465	0.137	CbGbCtD
Sorafenib—Hepatic pain—Topotecan—cervical cancer	0.0394	0.239	CcSEcCtD
Sorafenib—Tumour pain—Topotecan—cervical cancer	0.0348	0.211	CcSEcCtD
Sorafenib—Mucosal inflammation—Topotecan—cervical cancer	0.00593	0.036	CcSEcCtD
Sorafenib—Interstitial lung disease—Topotecan—cervical cancer	0.00464	0.0282	CcSEcCtD
Sorafenib—Pleural effusion—Topotecan—cervical cancer	0.00429	0.026	CcSEcCtD
Sorafenib—Blood bilirubin increased—Topotecan—cervical cancer	0.00347	0.0211	CcSEcCtD
Sorafenib—Neuropathy—Topotecan—cervical cancer	0.00308	0.0187	CcSEcCtD
Sorafenib—Neoplasm—Topotecan—cervical cancer	0.00297	0.018	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00215	0.013	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.0021	0.0128	CcSEcCtD
Sorafenib—TIE1—epithelium—cervical cancer	0.00199	0.00741	CbGeAlD
Sorafenib—HIPK3—renal system—cervical cancer	0.00198	0.00735	CbGeAlD
Sorafenib—TIE1—uterine cervix—cervical cancer	0.00197	0.00734	CbGeAlD
Sorafenib—ZAK—endometrium—cervical cancer	0.00195	0.00726	CbGeAlD
Sorafenib—Neutropenia—Topotecan—cervical cancer	0.00193	0.0117	CcSEcCtD
Sorafenib—HIPK3—endometrium—cervical cancer	0.00191	0.00711	CbGeAlD
Sorafenib—MAPK11—female reproductive system—cervical cancer	0.0019	0.00707	CbGeAlD
Sorafenib—ZAK—mammalian vulva—cervical cancer	0.00189	0.00702	CbGeAlD
Sorafenib—TIE1—decidua—cervical cancer	0.00188	0.007	CbGeAlD
Sorafenib—CDK7—female reproductive system—cervical cancer	0.00187	0.00696	CbGeAlD
Sorafenib—Pneumonia—Topotecan—cervical cancer	0.00185	0.0112	CcSEcCtD
Sorafenib—AURKC—female reproductive system—cervical cancer	0.00184	0.00685	CbGeAlD
Sorafenib—Infestation NOS—Topotecan—cervical cancer	0.00184	0.0111	CcSEcCtD
Sorafenib—Infestation—Topotecan—cervical cancer	0.00184	0.0111	CcSEcCtD
Sorafenib—Neuropathy peripheral—Topotecan—cervical cancer	0.0018	0.0109	CcSEcCtD
Sorafenib—ZAK—uterus—cervical cancer	0.0018	0.00669	CbGeAlD
Sorafenib—Stomatitis—Topotecan—cervical cancer	0.00179	0.0109	CcSEcCtD
Sorafenib—Hepatobiliary disease—Topotecan—cervical cancer	0.00174	0.0105	CcSEcCtD
Sorafenib—Epistaxis—Topotecan—cervical cancer	0.00173	0.0105	CcSEcCtD
Sorafenib—MAPK11—female gonad—cervical cancer	0.00173	0.00644	CbGeAlD
Sorafenib—BRAF—endometrium—cervical cancer	0.00171	0.00637	CbGeAlD
Sorafenib—EPHA6—female reproductive system—cervical cancer	0.00171	0.00635	CbGeAlD
Sorafenib—CDK7—female gonad—cervical cancer	0.0017	0.00633	CbGeAlD
Sorafenib—TAOK2—female gonad—cervical cancer	0.00169	0.00628	CbGeAlD
Sorafenib—TAOK2—vagina—cervical cancer	0.00168	0.00624	CbGeAlD
Sorafenib—Haemoglobin—Topotecan—cervical cancer	0.00166	0.0101	CcSEcCtD
Sorafenib—Haemorrhage—Topotecan—cervical cancer	0.00165	0.01	CcSEcCtD
Sorafenib—TIE1—uterus—cervical cancer	0.00165	0.00612	CbGeAlD
Sorafenib—FLT4—epithelium—cervical cancer	0.00165	0.00612	CbGeAlD
Sorafenib—ZAK—female reproductive system—cervical cancer	0.00162	0.00601	CbGeAlD
Sorafenib—FGFR1—uterine cervix—cervical cancer	0.00161	0.00599	CbGeAlD
Sorafenib—HIPK3—female reproductive system—cervical cancer	0.00158	0.00589	CbGeAlD
Sorafenib—EPHX2—mammalian vulva—cervical cancer	0.00158	0.00589	CbGeAlD
Sorafenib—BRAF—uterus—cervical cancer	0.00158	0.00587	CbGeAlD
Sorafenib—FLT4—decidua—cervical cancer	0.00155	0.00578	CbGeAlD
Sorafenib—MAP3K19—female reproductive system—cervical cancer	0.00155	0.00577	CbGeAlD
Sorafenib—UGT1A9—renal system—cervical cancer	0.00155	0.00576	CbGeAlD
Sorafenib—FGFR1—decidua—cervical cancer	0.00153	0.0057	CbGeAlD
Sorafenib—MAP3K7—uterine cervix—cervical cancer	0.00152	0.00567	CbGeAlD
Sorafenib—EPHX2—uterus—cervical cancer	0.00151	0.00561	CbGeAlD
Sorafenib—Angiopathy—Topotecan—cervical cancer	0.0015	0.00908	CcSEcCtD
Sorafenib—Immune system disorder—Topotecan—cervical cancer	0.00149	0.00904	CcSEcCtD
Sorafenib—MKNK2—epithelium—cervical cancer	0.00149	0.00554	CbGeAlD
Sorafenib—Mediastinal disorder—Topotecan—cervical cancer	0.00149	0.00902	CcSEcCtD
Sorafenib—TIE1—female reproductive system—cervical cancer	0.00148	0.0055	CbGeAlD
Sorafenib—MKNK2—uterine cervix—cervical cancer	0.00148	0.00549	CbGeAlD
Sorafenib—ZAK—female gonad—cervical cancer	0.00147	0.00547	CbGeAlD
Sorafenib—ZAK—vagina—cervical cancer	0.00146	0.00544	CbGeAlD
Sorafenib—MKNK1—uterine cervix—cervical cancer	0.00146	0.00542	CbGeAlD
Sorafenib—Alopecia—Topotecan—cervical cancer	0.00146	0.00884	CcSEcCtD
Sorafenib—RET—epithelium—cervical cancer	0.00145	0.0054	CbGeAlD
Sorafenib—MAP3K7—decidua—cervical cancer	0.00145	0.0054	CbGeAlD
Sorafenib—HIPK3—female gonad—cervical cancer	0.00144	0.00536	CbGeAlD
Sorafenib—Malnutrition—Topotecan—cervical cancer	0.00144	0.00871	CcSEcCtD
Sorafenib—HIPK3—vagina—cervical cancer	0.00143	0.00532	CbGeAlD
Sorafenib—FGFR1—mammalian vulva—cervical cancer	0.00141	0.00524	CbGeAlD
Sorafenib—MKNK2—decidua—cervical cancer	0.00141	0.00523	CbGeAlD
Sorafenib—MKNK1—decidua—cervical cancer	0.00139	0.00517	CbGeAlD
Sorafenib—MKNK2—renal system—cervical cancer	0.00138	0.00514	CbGeAlD
Sorafenib—Muscle spasms—Topotecan—cervical cancer	0.00138	0.00838	CcSEcCtD
Sorafenib—MAP3K7—endometrium—cervical cancer	0.00138	0.00513	CbGeAlD
Sorafenib—RET—decidua—cervical cancer	0.00137	0.0051	CbGeAlD
Sorafenib—RET—renal system—cervical cancer	0.00135	0.00501	CbGeAlD
Sorafenib—TIE1—female gonad—cervical cancer	0.00135	0.00501	CbGeAlD
Sorafenib—FLT3—female reproductive system—cervical cancer	0.00135	0.00501	CbGeAlD
Sorafenib—FGFR1—uterus—cervical cancer	0.00134	0.00499	CbGeAlD
Sorafenib—MKNK2—endometrium—cervical cancer	0.00134	0.00497	CbGeAlD
Sorafenib—RALBP1—uterine cervix—cervical cancer	0.00133	0.00496	CbGeAlD
Sorafenib—MAP3K7—mammalian vulva—cervical cancer	0.00133	0.00496	CbGeAlD
Sorafenib—Anaemia—Topotecan—cervical cancer	0.00133	0.00805	CcSEcCtD
Sorafenib—MKNK1—endometrium—cervical cancer	0.00132	0.0049	CbGeAlD
Sorafenib—Angioedema—Topotecan—cervical cancer	0.00131	0.00796	CcSEcCtD
Sorafenib—MKNK2—mammalian vulva—cervical cancer	0.00129	0.00481	CbGeAlD
Sorafenib—BRAF—female gonad—cervical cancer	0.00129	0.0048	CbGeAlD
Sorafenib—Leukopenia—Topotecan—cervical cancer	0.00129	0.0078	CcSEcCtD
Sorafenib—BRAF—vagina—cervical cancer	0.00128	0.00477	CbGeAlD
Sorafenib—FLT1—epithelium—cervical cancer	0.00128	0.00476	CbGeAlD
Sorafenib—MKNK1—mammalian vulva—cervical cancer	0.00128	0.00474	CbGeAlD
Sorafenib—RAF1—epithelium—cervical cancer	0.00127	0.00473	CbGeAlD
Sorafenib—RALBP1—decidua—cervical cancer	0.00127	0.00473	CbGeAlD
Sorafenib—MAP3K7—uterus—cervical cancer	0.00127	0.00472	CbGeAlD
Sorafenib—FLT1—uterine cervix—cervical cancer	0.00127	0.00472	CbGeAlD
Sorafenib—RAF1—uterine cervix—cervical cancer	0.00126	0.00469	CbGeAlD
Sorafenib—EPHB6—uterine cervix—cervical cancer	0.00125	0.00466	CbGeAlD
Sorafenib—Cough—Topotecan—cervical cancer	0.00125	0.0076	CcSEcCtD
Sorafenib—RALBP1—renal system—cervical cancer	0.00125	0.00464	CbGeAlD
Sorafenib—EPHX2—female gonad—cervical cancer	0.00123	0.00459	CbGeAlD
Sorafenib—MKNK2—uterus—cervical cancer	0.00123	0.00458	CbGeAlD
Sorafenib—EPHX2—vagina—cervical cancer	0.00123	0.00456	CbGeAlD
Sorafenib—FLT3—female gonad—cervical cancer	0.00122	0.00455	CbGeAlD
Sorafenib—Myalgia—Topotecan—cervical cancer	0.00122	0.00742	CcSEcCtD
Sorafenib—Arthralgia—Topotecan—cervical cancer	0.00122	0.00742	CcSEcCtD
Sorafenib—FLT4—female reproductive system—cervical cancer	0.00122	0.00455	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00121	0.00737	CcSEcCtD
Sorafenib—FLT1—decidua—cervical cancer	0.00121	0.00449	CbGeAlD
Sorafenib—RALBP1—endometrium—cervical cancer	0.00121	0.00449	CbGeAlD
Sorafenib—RAF1—decidua—cervical cancer	0.0012	0.00447	CbGeAlD
Sorafenib—STK10—uterine cervix—cervical cancer	0.0012	0.00447	CbGeAlD
Sorafenib—EPHB6—decidua—cervical cancer	0.00119	0.00444	CbGeAlD
Sorafenib—FLT1—renal system—cervical cancer	0.00119	0.00441	CbGeAlD
Sorafenib—RAF1—renal system—cervical cancer	0.00118	0.00439	CbGeAlD
Sorafenib—Anaphylactic shock—Topotecan—cervical cancer	0.00117	0.00711	CcSEcCtD
Sorafenib—RALBP1—mammalian vulva—cervical cancer	0.00117	0.00434	CbGeAlD
Sorafenib—Infection—Topotecan—cervical cancer	0.00116	0.00706	CcSEcCtD
Sorafenib—Nervous system disorder—Topotecan—cervical cancer	0.00115	0.00697	CcSEcCtD
Sorafenib—Thrombocytopenia—Topotecan—cervical cancer	0.00115	0.00696	CcSEcCtD
Sorafenib—FLT1—endometrium—cervical cancer	0.00115	0.00427	CbGeAlD
Sorafenib—STK10—decidua—cervical cancer	0.00114	0.00425	CbGeAlD
Sorafenib—RAF1—endometrium—cervical cancer	0.00114	0.00424	CbGeAlD
Sorafenib—Skin disorder—Topotecan—cervical cancer	0.00114	0.00691	CcSEcCtD
Sorafenib—EPHB6—endometrium—cervical cancer	0.00113	0.00422	CbGeAlD
Sorafenib—PDGFRA—decidua—cervical cancer	0.00113	0.00421	CbGeAlD
Sorafenib—STK10—renal system—cervical cancer	0.00112	0.00418	CbGeAlD
Sorafenib—Anorexia—Topotecan—cervical cancer	0.00112	0.00678	CcSEcCtD
Sorafenib—MAPK11—lymph node—cervical cancer	0.00111	0.00414	CbGeAlD
Sorafenib—FLT4—female gonad—cervical cancer	0.00111	0.00414	CbGeAlD
Sorafenib—PDGFRA—renal system—cervical cancer	0.00111	0.00414	CbGeAlD
Sorafenib—RALBP1—uterus—cervical cancer	0.00111	0.00413	CbGeAlD
Sorafenib—FLT1—mammalian vulva—cervical cancer	0.00111	0.00413	CbGeAlD
Sorafenib—MKNK2—female reproductive system—cervical cancer	0.00111	0.00411	CbGeAlD
Sorafenib—RAF1—mammalian vulva—cervical cancer	0.0011	0.0041	CbGeAlD
Sorafenib—FGFR1—female gonad—cervical cancer	0.0011	0.00408	CbGeAlD
Sorafenib—EPHB6—mammalian vulva—cervical cancer	0.0011	0.00408	CbGeAlD
Sorafenib—CDK7—lymph node—cervical cancer	0.00109	0.00407	CbGeAlD
Sorafenib—MKNK1—female reproductive system—cervical cancer	0.00109	0.00406	CbGeAlD
Sorafenib—FGFR1—vagina—cervical cancer	0.00109	0.00406	CbGeAlD
Sorafenib—TAOK2—lymph node—cervical cancer	0.00109	0.00404	CbGeAlD
Sorafenib—KDR—epithelium—cervical cancer	0.00108	0.00402	CbGeAlD
Sorafenib—AURKC—lymph node—cervical cancer	0.00108	0.00401	CbGeAlD
Sorafenib—KDR—uterine cervix—cervical cancer	0.00107	0.00399	CbGeAlD
Sorafenib—MAP2K5—uterine cervix—cervical cancer	0.00107	0.00399	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00107	0.00648	CcSEcCtD
Sorafenib—UGT1A1—renal system—cervical cancer	0.00106	0.00395	CbGeAlD
Sorafenib—FLT1—uterus—cervical cancer	0.00106	0.00393	CbGeAlD
Sorafenib—RAF1—uterus—cervical cancer	0.00105	0.00391	CbGeAlD
Sorafenib—STK10—mammalian vulva—cervical cancer	0.00105	0.00391	CbGeAlD
Sorafenib—CSF1R—uterine cervix—cervical cancer	0.00105	0.00389	CbGeAlD
Sorafenib—Dyspnoea—Topotecan—cervical cancer	0.00104	0.00634	CcSEcCtD
Sorafenib—MAP3K7—female gonad—cervical cancer	0.00104	0.00386	CbGeAlD
Sorafenib—MAP3K7—vagina—cervical cancer	0.00103	0.00384	CbGeAlD
Sorafenib—Dyspepsia—Topotecan—cervical cancer	0.00103	0.00626	CcSEcCtD
Sorafenib—KDR—decidua—cervical cancer	0.00102	0.0038	CbGeAlD
Sorafenib—MAP2K5—decidua—cervical cancer	0.00102	0.0038	CbGeAlD
Sorafenib—Decreased appetite—Topotecan—cervical cancer	0.00102	0.00618	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Topotecan—cervical cancer	0.00101	0.00614	CcSEcCtD
Sorafenib—Fatigue—Topotecan—cervical cancer	0.00101	0.00613	CcSEcCtD
Sorafenib—MKNK2—female gonad—cervical cancer	0.00101	0.00374	CbGeAlD
Sorafenib—KDR—renal system—cervical cancer	0.001	0.00373	CbGeAlD
Sorafenib—Pain—Topotecan—cervical cancer	0.001	0.00608	CcSEcCtD
Sorafenib—Constipation—Topotecan—cervical cancer	0.001	0.00608	CcSEcCtD
Sorafenib—STK10—uterus—cervical cancer	0.001	0.00372	CbGeAlD
Sorafenib—MKNK2—vagina—cervical cancer	0.001	0.00372	CbGeAlD
Sorafenib—RALBP1—female reproductive system—cervical cancer	0.000999	0.00372	CbGeAlD
Sorafenib—CSF1R—decidua—cervical cancer	0.000997	0.00371	CbGeAlD
Sorafenib—MKNK1—female gonad—cervical cancer	0.000994	0.0037	CbGeAlD
Sorafenib—PDGFRA—uterus—cervical cancer	0.000991	0.00368	CbGeAlD
Sorafenib—MKNK1—vagina—cervical cancer	0.000988	0.00367	CbGeAlD
Sorafenib—KDR—endometrium—cervical cancer	0.00097	0.00361	CbGeAlD
Sorafenib—MAP2K5—endometrium—cervical cancer	0.00097	0.00361	CbGeAlD
Sorafenib—KIT—epithelium—cervical cancer	0.000958	0.00356	CbGeAlD
Sorafenib—Gastrointestinal pain—Topotecan—cervical cancer	0.000958	0.00581	CcSEcCtD
Sorafenib—FLT1—female reproductive system—cervical cancer	0.00095	0.00353	CbGeAlD
Sorafenib—KIT—uterine cervix—cervical cancer	0.00095	0.00353	CbGeAlD
Sorafenib—CSF1R—endometrium—cervical cancer	0.000947	0.00352	CbGeAlD
Sorafenib—ZAK—lymph node—cervical cancer	0.000946	0.00352	CbGeAlD
Sorafenib—RAF1—female reproductive system—cervical cancer	0.000945	0.00351	CbGeAlD
Sorafenib—KDR—mammalian vulva—cervical cancer	0.000938	0.00349	CbGeAlD
Sorafenib—MAP2K5—mammalian vulva—cervical cancer	0.000938	0.00349	CbGeAlD
Sorafenib—PDGFRB—epithelium—cervical cancer	0.000936	0.00348	CbGeAlD
Sorafenib—Urticaria—Topotecan—cervical cancer	0.000931	0.00565	CcSEcCtD
Sorafenib—PDGFRB—uterine cervix—cervical cancer	0.000928	0.00345	CbGeAlD
Sorafenib—Abdominal pain—Topotecan—cervical cancer	0.000927	0.00562	CcSEcCtD
Sorafenib—Body temperature increased—Topotecan—cervical cancer	0.000927	0.00562	CcSEcCtD
Sorafenib—HIPK3—lymph node—cervical cancer	0.000926	0.00344	CbGeAlD
Sorafenib—CSF1R—mammalian vulva—cervical cancer	0.000916	0.00341	CbGeAlD
Sorafenib—RALBP1—female gonad—cervical cancer	0.000909	0.00338	CbGeAlD
Sorafenib—KIT—decidua—cervical cancer	0.000905	0.00337	CbGeAlD
Sorafenib—RALBP1—vagina—cervical cancer	0.000904	0.00336	CbGeAlD
Sorafenib—STK10—female reproductive system—cervical cancer	0.0009	0.00335	CbGeAlD
Sorafenib—KDR—uterus—cervical cancer	0.000894	0.00332	CbGeAlD
Sorafenib—PDGFRA—female reproductive system—cervical cancer	0.000891	0.00331	CbGeAlD
Sorafenib—KIT—renal system—cervical cancer	0.000889	0.00331	CbGeAlD
Sorafenib—PDGFRB—decidua—cervical cancer	0.000884	0.00329	CbGeAlD
Sorafenib—CSF1R—uterus—cervical cancer	0.000872	0.00324	CbGeAlD
Sorafenib—PDGFRB—renal system—cervical cancer	0.000868	0.00323	CbGeAlD
Sorafenib—TIE1—lymph node—cervical cancer	0.000865	0.00322	CbGeAlD
Sorafenib—FLT1—female gonad—cervical cancer	0.000865	0.00322	CbGeAlD
Sorafenib—Hypersensitivity—Topotecan—cervical cancer	0.000864	0.00524	CcSEcCtD
Sorafenib—RAF1—female gonad—cervical cancer	0.00086	0.0032	CbGeAlD
Sorafenib—FLT1—vagina—cervical cancer	0.00086	0.0032	CbGeAlD
Sorafenib—KIT—endometrium—cervical cancer	0.000859	0.0032	CbGeAlD
Sorafenib—EPHB6—female gonad—cervical cancer	0.000855	0.00318	CbGeAlD
Sorafenib—RAF1—vagina—cervical cancer	0.000855	0.00318	CbGeAlD
Sorafenib—EPHB6—vagina—cervical cancer	0.00085	0.00316	CbGeAlD
Sorafenib—Asthenia—Topotecan—cervical cancer	0.000841	0.0051	CcSEcCtD
Sorafenib—PDGFRB—endometrium—cervical cancer	0.000839	0.00312	CbGeAlD
Sorafenib—KIT—mammalian vulva—cervical cancer	0.000831	0.00309	CbGeAlD
Sorafenib—BRAF—lymph node—cervical cancer	0.00083	0.00309	CbGeAlD
Sorafenib—Pruritus—Topotecan—cervical cancer	0.000829	0.00503	CcSEcCtD
Sorafenib—STK10—female gonad—cervical cancer	0.000819	0.00304	CbGeAlD
Sorafenib—STK10—vagina—cervical cancer	0.000814	0.00303	CbGeAlD
Sorafenib—PDGFRB—mammalian vulva—cervical cancer	0.000812	0.00302	CbGeAlD
Sorafenib—PDGFRA—female gonad—cervical cancer	0.00081	0.00301	CbGeAlD
Sorafenib—PDGFRA—vagina—cervical cancer	0.000805	0.003	CbGeAlD
Sorafenib—MAP2K5—female reproductive system—cervical cancer	0.000803	0.00299	CbGeAlD
Sorafenib—KDR—female reproductive system—cervical cancer	0.000803	0.00299	CbGeAlD
Sorafenib—Diarrhoea—Topotecan—cervical cancer	0.000802	0.00486	CcSEcCtD
Sorafenib—EPHX2—lymph node—cervical cancer	0.000793	0.00295	CbGeAlD
Sorafenib—KIT—uterus—cervical cancer	0.000792	0.00295	CbGeAlD
Sorafenib—FLT3—lymph node—cervical cancer	0.000787	0.00293	CbGeAlD
Sorafenib—CSF1R—female reproductive system—cervical cancer	0.000784	0.00292	CbGeAlD
Sorafenib—Dizziness—Topotecan—cervical cancer	0.000775	0.0047	CcSEcCtD
Sorafenib—PDGFRB—uterus—cervical cancer	0.000774	0.00288	CbGeAlD
Sorafenib—Vomiting—Topotecan—cervical cancer	0.000745	0.00452	CcSEcCtD
Sorafenib—Rash—Topotecan—cervical cancer	0.000739	0.00448	CcSEcCtD
Sorafenib—Dermatitis—Topotecan—cervical cancer	0.000738	0.00448	CcSEcCtD
Sorafenib—HTR2B—uterine cervix—cervical cancer	0.000735	0.00273	CbGeAlD
Sorafenib—Headache—Topotecan—cervical cancer	0.000734	0.00445	CcSEcCtD
Sorafenib—KDR—female gonad—cervical cancer	0.000731	0.00272	CbGeAlD
Sorafenib—MAP2K5—female gonad—cervical cancer	0.000731	0.00272	CbGeAlD
Sorafenib—MAP2K5—vagina—cervical cancer	0.000727	0.0027	CbGeAlD
Sorafenib—KDR—vagina—cervical cancer	0.000727	0.0027	CbGeAlD
Sorafenib—FLT4—lymph node—cervical cancer	0.000715	0.00266	CbGeAlD
Sorafenib—CSF1R—female gonad—cervical cancer	0.000713	0.00265	CbGeAlD
Sorafenib—KIT—female reproductive system—cervical cancer	0.000712	0.00265	CbGeAlD
Sorafenib—CSF1R—vagina—cervical cancer	0.000709	0.00264	CbGeAlD
Sorafenib—FGFR1—lymph node—cervical cancer	0.000705	0.00262	CbGeAlD
Sorafenib—HTR2B—decidua—cervical cancer	0.0007	0.0026	CbGeAlD
Sorafenib—Nausea—Topotecan—cervical cancer	0.000696	0.00422	CcSEcCtD
Sorafenib—PDGFRB—female reproductive system—cervical cancer	0.000695	0.00259	CbGeAlD
Sorafenib—ABCC4—renal system—cervical cancer	0.000691	0.00257	CbGeAlD
Sorafenib—ABCC2—renal system—cervical cancer	0.000669	0.00249	CbGeAlD
Sorafenib—MAP3K7—lymph node—cervical cancer	0.000668	0.00248	CbGeAlD
Sorafenib—HTR2B—endometrium—cervical cancer	0.000665	0.00247	CbGeAlD
Sorafenib—KIT—female gonad—cervical cancer	0.000648	0.00241	CbGeAlD
Sorafenib—MKNK2—lymph node—cervical cancer	0.000647	0.00241	CbGeAlD
Sorafenib—KIT—vagina—cervical cancer	0.000644	0.00239	CbGeAlD
Sorafenib—MKNK1—lymph node—cervical cancer	0.000639	0.00238	CbGeAlD
Sorafenib—PDGFRB—female gonad—cervical cancer	0.000633	0.00235	CbGeAlD
Sorafenib—RET—lymph node—cervical cancer	0.000631	0.00235	CbGeAlD
Sorafenib—PDGFRB—vagina—cervical cancer	0.000629	0.00234	CbGeAlD
Sorafenib—ABCC4—uterus—cervical cancer	0.000616	0.00229	CbGeAlD
Sorafenib—HTR2B—uterus—cervical cancer	0.000613	0.00228	CbGeAlD
Sorafenib—HTR2C—female reproductive system—cervical cancer	0.000586	0.00218	CbGeAlD
Sorafenib—RALBP1—lymph node—cervical cancer	0.000585	0.00217	CbGeAlD
Sorafenib—FLT1—lymph node—cervical cancer	0.000556	0.00207	CbGeAlD
Sorafenib—ABCC4—female reproductive system—cervical cancer	0.000554	0.00206	CbGeAlD
Sorafenib—RAF1—lymph node—cervical cancer	0.000553	0.00206	CbGeAlD
Sorafenib—HTR2B—female reproductive system—cervical cancer	0.000551	0.00205	CbGeAlD
Sorafenib—EPHB6—lymph node—cervical cancer	0.00055	0.00204	CbGeAlD
Sorafenib—ABCC2—female reproductive system—cervical cancer	0.000536	0.00199	CbGeAlD
Sorafenib—STK10—lymph node—cervical cancer	0.000526	0.00196	CbGeAlD
Sorafenib—ABCG2—uterine cervix—cervical cancer	0.000522	0.00194	CbGeAlD
Sorafenib—PDGFRA—lymph node—cervical cancer	0.000521	0.00194	CbGeAlD
Sorafenib—ABCC4—female gonad—cervical cancer	0.000504	0.00187	CbGeAlD
Sorafenib—CYP2C8—renal system—cervical cancer	0.000502	0.00187	CbGeAlD
Sorafenib—HTR2B—vagina—cervical cancer	0.000498	0.00185	CbGeAlD
Sorafenib—ABCG2—decidua—cervical cancer	0.000497	0.00185	CbGeAlD
Sorafenib—CYP2C8—endometrium—cervical cancer	0.000485	0.0018	CbGeAlD
Sorafenib—CYP3A5—uterine cervix—cervical cancer	0.000484	0.0018	CbGeAlD
Sorafenib—ABCG2—endometrium—cervical cancer	0.000472	0.00175	CbGeAlD
Sorafenib—MAP2K5—lymph node—cervical cancer	0.00047	0.00175	CbGeAlD
Sorafenib—KDR—lymph node—cervical cancer	0.00047	0.00175	CbGeAlD
Sorafenib—CYP1A2—renal system—cervical cancer	0.00047	0.00175	CbGeAlD
Sorafenib—CSF1R—lymph node—cervical cancer	0.000459	0.00171	CbGeAlD
Sorafenib—ABCG2—mammalian vulva—cervical cancer	0.000456	0.0017	CbGeAlD
Sorafenib—CYP3A5—renal system—cervical cancer	0.000453	0.00168	CbGeAlD
Sorafenib—CYP2B6—renal system—cervical cancer	0.00045	0.00167	CbGeAlD
Sorafenib—ABCG2—uterus—cervical cancer	0.000435	0.00162	CbGeAlD
Sorafenib—CYP2C19—vagina—cervical cancer	0.000417	0.00155	CbGeAlD
Sorafenib—KIT—lymph node—cervical cancer	0.000417	0.00155	CbGeAlD
Sorafenib—PDGFRB—lymph node—cervical cancer	0.000407	0.00151	CbGeAlD
Sorafenib—CYP2C8—female reproductive system—cervical cancer	0.000402	0.00149	CbGeAlD
Sorafenib—CYP2C8—vagina—cervical cancer	0.000364	0.00135	CbGeAlD
Sorafenib—CYP2B6—female reproductive system—cervical cancer	0.000361	0.00134	CbGeAlD
Sorafenib—CYP2C9—female reproductive system—cervical cancer	0.000357	0.00133	CbGeAlD
Sorafenib—ABCG2—female gonad—cervical cancer	0.000356	0.00132	CbGeAlD
Sorafenib—ABCG2—vagina—cervical cancer	0.000353	0.00131	CbGeAlD
Sorafenib—CYP3A4—renal system—cervical cancer	0.00034	0.00126	CbGeAlD
Sorafenib—CYP2D6—renal system—cervical cancer	0.000335	0.00124	CbGeAlD
Sorafenib—CYP3A5—female gonad—cervical cancer	0.00033	0.00123	CbGeAlD
Sorafenib—CYP3A5—vagina—cervical cancer	0.000328	0.00122	CbGeAlD
Sorafenib—CYP2B6—vagina—cervical cancer	0.000326	0.00121	CbGeAlD
Sorafenib—ABCC4—lymph node—cervical cancer	0.000324	0.0012	CbGeAlD
Sorafenib—HTR2B—lymph node—cervical cancer	0.000322	0.0012	CbGeAlD
Sorafenib—ABCC2—lymph node—cervical cancer	0.000314	0.00117	CbGeAlD
Sorafenib—CYP3A4—female reproductive system—cervical cancer	0.000272	0.00101	CbGeAlD
Sorafenib—CYP2D6—female reproductive system—cervical cancer	0.000268	0.000996	CbGeAlD
Sorafenib—ABCB1—epithelium—cervical cancer	0.000259	0.000965	CbGeAlD
Sorafenib—ABCB1—uterine cervix—cervical cancer	0.000257	0.000957	CbGeAlD
Sorafenib—ABCB1—decidua—cervical cancer	0.000245	0.000911	CbGeAlD
Sorafenib—CYP2D6—female gonad—cervical cancer	0.000244	0.000907	CbGeAlD
Sorafenib—ABCB1—renal system—cervical cancer	0.000241	0.000895	CbGeAlD
Sorafenib—ABCB1—endometrium—cervical cancer	0.000233	0.000865	CbGeAlD
Sorafenib—ABCG2—lymph node—cervical cancer	0.000229	0.00085	CbGeAlD
Sorafenib—ABCB1—mammalian vulva—cervical cancer	0.000225	0.000837	CbGeAlD
Sorafenib—ABCB1—uterus—cervical cancer	0.000214	0.000797	CbGeAlD
Sorafenib—ABCB1—female reproductive system—cervical cancer	0.000193	0.000717	CbGeAlD
Sorafenib—ABCB1—female gonad—cervical cancer	0.000175	0.000652	CbGeAlD
Sorafenib—ABCB1—vagina—cervical cancer	0.000174	0.000648	CbGeAlD
Sorafenib—ABCB1—lymph node—cervical cancer	0.000113	0.000419	CbGeAlD
Sorafenib—KIT—Innate Immune System—EGFR—cervical cancer	2.63e-05	0.000116	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—EGFR—cervical cancer	2.63e-05	0.000116	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—EGFR—cervical cancer	2.62e-05	0.000116	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOTCH2—cervical cancer	2.6e-05	0.000115	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FGFR3—cervical cancer	2.59e-05	0.000114	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—EGFR—cervical cancer	2.58e-05	0.000114	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NOTCH1—cervical cancer	2.55e-05	0.000113	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NOTCH1—cervical cancer	2.55e-05	0.000112	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—EGFR—cervical cancer	2.53e-05	0.000112	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—EGFR—cervical cancer	2.53e-05	0.000112	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CTNNB1—cervical cancer	2.53e-05	0.000111	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CASP8—cervical cancer	2.52e-05	0.000111	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—CASP3—cervical cancer	2.52e-05	0.000111	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CASP8—cervical cancer	2.51e-05	0.000111	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—EGFR—cervical cancer	2.5e-05	0.00011	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HES1—cervical cancer	2.5e-05	0.00011	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HES1—cervical cancer	2.5e-05	0.00011	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—STAT3—cervical cancer	2.49e-05	0.00011	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NOTCH1—cervical cancer	2.49e-05	0.00011	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—EGFR—cervical cancer	2.49e-05	0.00011	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOTCH2—cervical cancer	2.47e-05	0.000109	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FGFR3—cervical cancer	2.44e-05	0.000108	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NOTCH1—cervical cancer	2.43e-05	0.000107	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—CTNNB1—cervical cancer	2.43e-05	0.000107	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TERT—cervical cancer	2.42e-05	0.000107	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—MTOR—cervical cancer	2.42e-05	0.000107	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD4—cervical cancer	2.42e-05	0.000107	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TERT—cervical cancer	2.4e-05	0.000106	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—EGFR—cervical cancer	2.4e-05	0.000106	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—EGFR—cervical cancer	2.39e-05	0.000106	CbGpPWpGaD
Sorafenib—RAF1—Disease—MTHFR—cervical cancer	2.38e-05	0.000105	CbGpPWpGaD
Sorafenib—RAF1—Disease—TERT—cervical cancer	2.37e-05	0.000105	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CA9—cervical cancer	2.37e-05	0.000105	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HES1—cervical cancer	2.37e-05	0.000104	CbGpPWpGaD
Sorafenib—CDK7—Disease—STAT3—cervical cancer	2.36e-05	0.000104	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HES1—cervical cancer	2.36e-05	0.000104	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FGFR3—cervical cancer	2.36e-05	0.000104	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—STAT3—cervical cancer	2.35e-05	0.000104	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CA9—cervical cancer	2.32e-05	0.000102	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOTCH2—cervical cancer	2.31e-05	0.000102	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NOTCH1—cervical cancer	2.29e-05	0.000101	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	2.29e-05	0.000101	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—EGFR—cervical cancer	2.27e-05	0.0001	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CASP8—cervical cancer	2.26e-05	9.99e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—EGFR—cervical cancer	2.25e-05	9.91e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGFR3—cervical cancer	2.23e-05	9.82e-05	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TP53—cervical cancer	2.22e-05	9.8e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MTOR—cervical cancer	2.21e-05	9.77e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—CD4—cervical cancer	2.21e-05	9.75e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGFR3—cervical cancer	2.2e-05	9.73e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TP53—cervical cancer	2.2e-05	9.7e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TERT—cervical cancer	2.19e-05	9.65e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TERT—cervical cancer	2.19e-05	9.65e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—MTOR—cervical cancer	2.18e-05	9.63e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—MTOR—cervical cancer	2.18e-05	9.63e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CA9—cervical cancer	2.18e-05	9.63e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD4—cervical cancer	2.18e-05	9.62e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD4—cervical cancer	2.18e-05	9.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—FGFR3—cervical cancer	2.18e-05	9.61e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CA9—cervical cancer	2.16e-05	9.55e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TP53—cervical cancer	2.16e-05	9.54e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—EGFR—cervical cancer	2.16e-05	9.51e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—EGFR—cervical cancer	2.15e-05	9.48e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CTNNB1—cervical cancer	2.15e-05	9.47e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—EGFR—cervical cancer	2.13e-05	9.42e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HES1—cervical cancer	2.13e-05	9.39e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—STAT3—cervical cancer	2.11e-05	9.33e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NOTCH1—cervical cancer	2.09e-05	9.22e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TERT—cervical cancer	2.07e-05	9.16e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—MTOR—cervical cancer	2.07e-05	9.14e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TERT—cervical cancer	2.07e-05	9.13e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NOTCH1—cervical cancer	2.07e-05	9.13e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD4—cervical cancer	2.07e-05	9.13e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—MTOR—cervical cancer	2.07e-05	9.12e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD4—cervical cancer	2.06e-05	9.1e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—MTHFR—cervical cancer	2.05e-05	9.04e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—MTHFR—cervical cancer	2.05e-05	9.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOTCH1—cervical cancer	2.04e-05	9.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HES1—cervical cancer	2.03e-05	8.95e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CASP8—cervical cancer	2.02e-05	8.9e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MTOR—cervical cancer	2.02e-05	8.89e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—CD4—cervical cancer	2.01e-05	8.88e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGFR3—cervical cancer	2.01e-05	8.85e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGFR3—cervical cancer	2.01e-05	8.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—EGFR—cervical cancer	2e-05	8.83e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOTCH2—cervical cancer	2e-05	8.81e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—CTNNB1—cervical cancer	1.96e-05	8.66e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—CTNNB1—cervical cancer	1.94e-05	8.54e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CTNNB1—cervical cancer	1.94e-05	8.54e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—EGFR—cervical cancer	1.92e-05	8.48e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—EGFR—cervical cancer	1.92e-05	8.48e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.92e-05	8.47e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MTOR—cervical cancer	1.91e-05	8.44e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CD4—cervical cancer	1.91e-05	8.43e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MTOR—cervical cancer	1.91e-05	8.42e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CD4—cervical cancer	1.9e-05	8.4e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGFR3—cervical cancer	1.9e-05	8.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGFR3—cervical cancer	1.9e-05	8.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HES1—cervical cancer	1.9e-05	8.37e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NOTCH1—cervical cancer	1.88e-05	8.31e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NOTCH1—cervical cancer	1.88e-05	8.31e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—STAT3—cervical cancer	1.87e-05	8.26e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MTOR—cervical cancer	1.87e-05	8.24e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—cervical cancer	1.87e-05	8.24e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TERT—cervical cancer	1.86e-05	8.23e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—MTOR—cervical cancer	1.86e-05	8.22e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD4—cervical cancer	1.86e-05	8.2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CA9—cervical cancer	1.85e-05	8.16e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CTNNB1—cervical cancer	1.84e-05	8.11e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CTNNB1—cervical cancer	1.83e-05	8.08e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MTOR—cervical cancer	1.82e-05	8.03e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—cervical cancer	1.79e-05	7.91e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NOTCH1—cervical cancer	1.79e-05	7.89e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—CTNNB1—cervical cancer	1.79e-05	7.89e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NOTCH1—cervical cancer	1.78e-05	7.87e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TERT—cervical cancer	1.78e-05	7.85e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MTHFR—cervical cancer	1.74e-05	7.67e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MTHFR—cervical cancer	1.72e-05	7.6e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MTOR—cervical cancer	1.72e-05	7.59e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CASP3—cervical cancer	1.72e-05	7.58e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD4—cervical cancer	1.72e-05	7.57e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—STAT3—cervical cancer	1.71e-05	7.55e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGFR3—cervical cancer	1.71e-05	7.55e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—EGFR—cervical cancer	1.7e-05	7.5e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CTNNB1—cervical cancer	1.7e-05	7.48e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CTNNB1—cervical cancer	1.69e-05	7.46e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—STAT3—cervical cancer	1.69e-05	7.44e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—STAT3—cervical cancer	1.69e-05	7.44e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CASP3—cervical cancer	1.67e-05	7.39e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TERT—cervical cancer	1.66e-05	7.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MTOR—cervical cancer	1.66e-05	7.32e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—cervical cancer	1.66e-05	7.31e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CTNNB1—cervical cancer	1.66e-05	7.31e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CTNNB1—cervical cancer	1.65e-05	7.28e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HES1—cervical cancer	1.64e-05	7.22e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGFR3—cervical cancer	1.63e-05	7.2e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CTNNB1—cervical cancer	1.61e-05	7.12e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—cervical cancer	1.61e-05	7.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOTCH1—cervical cancer	1.61e-05	7.09e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—STAT3—cervical cancer	1.6e-05	7.07e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—STAT3—cervical cancer	1.6e-05	7.05e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MTOR—cervical cancer	1.57e-05	6.91e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—STAT3—cervical cancer	1.56e-05	6.87e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—EGFR—cervical cancer	1.56e-05	6.86e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MTOR—cervical cancer	1.55e-05	6.84e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—EGFR—cervical cancer	1.53e-05	6.77e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EGFR—cervical cancer	1.53e-05	6.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MTOR—cervical cancer	1.53e-05	6.76e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOTCH1—cervical cancer	1.53e-05	6.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—cervical cancer	1.53e-05	6.75e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGFR3—cervical cancer	1.53e-05	6.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CTNNB1—cervical cancer	1.52e-05	6.72e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—STAT3—cervical cancer	1.48e-05	6.52e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—STAT3—cervical cancer	1.47e-05	6.51e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CTNNB1—cervical cancer	1.47e-05	6.49e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EGFR—cervical cancer	1.46e-05	6.42e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EGFR—cervical cancer	1.45e-05	6.41e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—STAT3—cervical cancer	1.44e-05	6.37e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CASP3—cervical cancer	1.44e-05	6.35e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—STAT3—cervical cancer	1.44e-05	6.35e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TERT—cervical cancer	1.43e-05	6.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOTCH1—cervical cancer	1.43e-05	6.32e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CA9—cervical cancer	1.43e-05	6.3e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CASP3—cervical cancer	1.43e-05	6.29e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EGFR—cervical cancer	1.42e-05	6.25e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MTOR—cervical cancer	1.41e-05	6.23e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MTOR—cervical cancer	1.41e-05	6.23e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—STAT3—cervical cancer	1.41e-05	6.21e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CTNNB1—cervical cancer	1.39e-05	6.12e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CTNNB1—cervical cancer	1.37e-05	6.07e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—EGFR—cervical cancer	1.36e-05	6.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CTNNB1—cervical cancer	1.36e-05	5.99e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EGFR—cervical cancer	1.34e-05	5.93e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EGFR—cervical cancer	1.34e-05	5.91e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MTOR—cervical cancer	1.34e-05	5.91e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MTOR—cervical cancer	1.34e-05	5.9e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—STAT3—cervical cancer	1.33e-05	5.86e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGFR3—cervical cancer	1.32e-05	5.81e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EGFR—cervical cancer	1.31e-05	5.79e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EGFR—cervical cancer	1.31e-05	5.77e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CASP3—cervical cancer	1.3e-05	5.73e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CASP3—cervical cancer	1.3e-05	5.73e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—STAT3—cervical cancer	1.28e-05	5.66e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EGFR—cervical cancer	1.28e-05	5.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—EGFR—cervical cancer	1.28e-05	5.63e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MTHFR—cervical cancer	1.27e-05	5.62e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CTNNB1—cervical cancer	1.25e-05	5.52e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CTNNB1—cervical cancer	1.25e-05	5.52e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MTHFR—cervical cancer	1.25e-05	5.5e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOTCH1—cervical cancer	1.24e-05	5.45e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CASP3—cervical cancer	1.23e-05	5.44e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CASP3—cervical cancer	1.23e-05	5.42e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—STAT3—cervical cancer	1.21e-05	5.34e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EGFR—cervical cancer	1.21e-05	5.33e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MTOR—cervical cancer	1.2e-05	5.31e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—STAT3—cervical cancer	1.2e-05	5.29e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CTNNB1—cervical cancer	1.19e-05	5.24e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CTNNB1—cervical cancer	1.18e-05	5.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—STAT3—cervical cancer	1.18e-05	5.22e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EGFR—cervical cancer	1.17e-05	5.14e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MTOR—cervical cancer	1.15e-05	5.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CASP3—cervical cancer	1.11e-05	4.89e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—cervical cancer	1.1e-05	4.86e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—cervical cancer	1.1e-05	4.86e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—cervical cancer	1.1e-05	4.85e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—STAT3—cervical cancer	1.09e-05	4.81e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—STAT3—cervical cancer	1.09e-05	4.81e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—cervical cancer	1.09e-05	4.81e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—cervical cancer	1.08e-05	4.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—cervical cancer	1.08e-05	4.75e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—cervical cancer	1.07e-05	4.74e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MTOR—cervical cancer	1.07e-05	4.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CTNNB1—cervical cancer	1.07e-05	4.71e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CASP3—cervical cancer	1.06e-05	4.66e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STAT3—cervical cancer	1.04e-05	4.57e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—cervical cancer	1.03e-05	4.56e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CTNNB1—cervical cancer	1.02e-05	4.49e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—cervical cancer	9.91e-06	4.37e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—cervical cancer	9.91e-06	4.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—cervical cancer	9.87e-06	4.35e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—cervical cancer	9.63e-06	4.25e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—cervical cancer	9.51e-06	4.2e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—cervical cancer	9.41e-06	4.15e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—cervical cancer	9.4e-06	4.15e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—cervical cancer	9.38e-06	4.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—cervical cancer	9.3e-06	4.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MTOR—cervical cancer	9.26e-06	4.09e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—cervical cancer	9.23e-06	4.07e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—cervical cancer	9.15e-06	4.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—cervical cancer	8.87e-06	3.91e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—cervical cancer	8.86e-06	3.91e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—cervical cancer	8.78e-06	3.87e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—cervical cancer	8.52e-06	3.76e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—cervical cancer	8.45e-06	3.73e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—cervical cancer	8.32e-06	3.67e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—cervical cancer	8.32e-06	3.67e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—cervical cancer	8.29e-06	3.66e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—cervical cancer	8.21e-06	3.62e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—cervical cancer	8.06e-06	3.56e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—cervical cancer	7.9e-06	3.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—cervical cancer	7.88e-06	3.48e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—cervical cancer	7.54e-06	3.33e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—cervical cancer	7.5e-06	3.31e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—cervical cancer	7.16e-06	3.16e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—cervical cancer	7.1e-06	3.13e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—cervical cancer	6.77e-06	2.99e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—cervical cancer	6.5e-06	2.87e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—cervical cancer	6.33e-06	2.79e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—cervical cancer	5.79e-06	2.56e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—cervical cancer	5.46e-06	2.41e-05	CbGpPWpGaD
